The Flavored-Vape Authorization Is the Wrong Test of the FDA’s New Tobacco Posture. The Right Test Is the Next Two Months.

On May 5, the FDA authorized four fruit- and menthol-flavored e-cigarette products from a single Los Angeles manufacturer, Glas Inc. They are the first non-tobacco, non-menthol flavored ENDS products ever to receive marketing authorization in the United States. Six days later, STAT News reported on a separate enforcement-discretion guidance under which the agency will not prioritize action against manufacturers selling flavored vapes without authorization, so long as those manufacturers have filed a Premarket Tobacco Product Application and submitted what the FDA deems sufficient data. Critics, including the American Lung Association, called the new posture a “get-out-of-jail-free card” for industry.

Both of those stories are real. Both will get most of the attention this month. And both are the wrong place to look if you want to understand where the FDA’s tobacco policy is actually heading.

The right place to look is June 20.

What actually changed on May 5

The Glas products clear a high technological bar that, until this month, the FDA had only described in theory. Each device requires government-ID age verification. Each device pairs by Bluetooth to a single verified smartphone. The companion app runs biometric check-ins at random intervals. The applicant demonstrated that adults over 21 could complete verification and use the device, and that youth and young adults — testing the same product — could not. The FDA’s authorization, on its face, is a policy victory for the agency’s longstanding position: a flavored ENDS product may be marketed only when the application shows that the benefit to adults trying to quit cigarettes outweighs the risk of pulling youth into nicotine use.

That is the right framework. The question is whether the May 5 decision is a faithful application of it or a wedge.

Two pieces of context belong here.

One: the most recent National Youth Tobacco Survey found that 5.9% of middle- and high-school students used e-cigarettes in 2024 — the lowest rate in a decade. Youth tobacco use overall fell from 2.80 million in 2023 to 2.25 million in 2024. The post-2020 flavor crackdown is one plausible contributor; it is not the only one, and the data cannot prove causation. But the decline is the empirical baseline against which May 5’s decision will be judged, and the FDA has explicitly committed to suspending or withdrawing authorization if there is a “notable increase in use of the products among youth.”

Two: the same year that youth use hit a decade low, Truth Initiative reported that 67% of young-adult nicotine users plan to quit in 2026 — up from 48% the prior year. But the share of daily youth e-cigarette users who had tried and failed to quit jumped from 28.2% (2020) to 53% (2024). Seventy-six percent of teen vapers in one Truth Initiative study reported using within 30 minutes of waking — a hallmark indicator of dependence. Lower prevalence has not produced a less dependent user base. It has produced a smaller, more deeply hooked one.

The May 11 STAT analysis matters because the FDA’s enforcement-discretion guidance applies to a much larger universe of products than the four Glas SKUs. The Glas authorization is bound by data, biometrics, and a single manufacturer’s compliance posture. The enforcement guidance is bound by paperwork — a filed PMTA and “sufficient data” — and applies to every manufacturer that meets those two conditions. The American Lung Association’s “get-out-of-jail-free” critique is directed at the second document, not the first.

Why June 20 is the real test

The single tobacco-policy decision that will tell us the most about the FDA’s actual public-health posture is not a flavored-vape authorization. It is the cytisinicline PDUFA on June 20, 2026 — 33 days from today.

It is the cytisinicline PDUFA on June 20, 2026 — 33 days from today.

Cytisinicline is a plant-derived nicotinic-receptor partial agonist. The phase 3 program — ORCA-2 and ORCA-3 — covered more than 2,000 participants. The ORCA-OL long-term safety trial cleared its last participant in October 2025, with 334 people completing a full year of treatment, exceeding the FDA’s pre-NDA safety request. Achieve Life Sciences also holds a Commissioner’s National Priority Voucher for the separate e-cigarette / vaping cessation indication, which would compress that secondary review to one to two months.

If approved on June 20, cytisinicline will be the first new smoking-cessation pharmacotherapy in roughly twenty years. It will arrive at a moment when 67% of young-adult nicotine users say they want to quit, when teen vapers are in unprecedented levels of dependence, and when the existing pharmacopeia — varenicline, bupropion, nicotine replacement therapy — has not been substantially updated since most of those users were born.

That is the actual test of the FDA’s tobacco posture: does the agency act with the same speed on the cessation side as it does on the authorization side? Does it grant cytisinicline a clean approval, with labeling that meaningfully recognizes the vaping use case? Does it then move fast on the CNPV-eligible e-cigarette indication? Or does the cessation pathway get the same enforcement-discretion-style ambiguity that the American Lung Association called out in the broader May guidance?

A regulator that authorizes new flavors for adult smokers and approves new cessation pharmacotherapy for adults trying to quit is operating a coherent public-health framework. A regulator that does the first without the second is doing industrial policy.

What this means for people in recovery

If you are reading this because someone you love is trying to quit vaping or pouches, the most useful thing you can take from the past two weeks is that the cessation pipeline is real and is about to get something new. You do not have to settle for what has been on the shelf since 2006.

Three things are true right now and will be true in different proportions in a month:

First, the most-prescribed cessation medications today — varenicline, bupropion, nicotine replacement — still work, and access is still better than it was five years ago, particularly through telehealth. If June 20 produces a clean approval, the field will gain a serious additional option; until then, the existing tools are not less effective than they were last month.

Second, the youth dependence pattern is real and is largely independent of which products are on shelves. A teenager who can’t get through 30 minutes of being awake without a vape needs a treatment plan, not just a policy change. Family-engagement frameworks like Truth Initiative’s This is Quitting program have been an underrated intervention in this category.

Third, dependence is a clinical category, not a moral one. If you or someone you love is in this position, the framing that tends to work — in both peer support and clinical care — is the same one that works in every other substance class: the addiction is not the person, the relapse is not the failure, and the right response to a setback is not shame but a faster connection to support.

If you are in Arizona and looking for cessation support that fits your insurance and your life, Rize can help you navigate the local options.

---

988 / SAMHSA’s National Helpline: Call or text 988 for mental-health crisis support. For substance-use treatment referrals, call 1-800-662-HELP (4357) — free, confidential, 24/7, available in English and Spanish.